Xolair 300 MG/2 ML autoinject 2ML

Ended Awarded Last action

Contract number
SPE2DR26FBPPQ
Awardee
Awarding agency
Obligated
$13,091

Award facts

Contract value 100% obligated
$13,091.16 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
424210 Drugs and Druggists' Sundries Merchant Wholesalers
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Park Ridge, IL 60068, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Logistics Agency issued a $13,091.16 delivery order to DMS Pharmaceutical Group Inc. on February 6, 2026, for Xolair 300 mg/2 ml autoinjector under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V).

DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, Illinois. The order has an ultimate completion date of March 2, 2026. PPV-G GEN V is DLA's single-award indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables to support Department of Defense healthcare operations worldwide.

Quick answers

Who was awarded contract SPE2DR26FBPPQ?

SPE2DR26FBPPQ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 6, 2026.

How much is contract SPE2DR26FBPPQ worth?

The government has obligated $13,091 on SPE2DR26FBPPQ.

Is contract SPE2DR26FBPPQ an order under another contract?

Yes. SPE2DR26FBPPQ is a delivery order under SPE2DR25D9309, an indefinite delivery contract.

Was contract SPE2DR26FBPPQ competed?

The extent of competition for SPE2DR26FBPPQ was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award